Hims & Hers (HIMS) Jumps 14.4% W/W Ahead of Q2 Earnings

We recently published 10 Stocks Surprise Wall Street with Double-Digit Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best-performing stocks on Friday.

Telehealth giant Hims & Hers saw its share prices increase by 14.4 percent week-on-week, from $50.38 to $57.65 on Friday, as investors began repositioning portfolios ahead of its earnings results while taking path from an investment firm’s bullish rating for its stock.

According to the company, it is scheduled to announce the results of its second quarter earnings performance after market close next Monday, August 4.

Last week, Hims & Hers Health, Inc. (NYSE:HIMS) earned a “strong buy” recommendation from Zacks Research on expectations that its 2025 earnings per share will improve by 177.8 percent year-on-year.

Zacks also underscored Hims & Hers Health, Inc.’s (NYSE:HIMS) expansion program with the recent acquisition of ZAVA, a European digital health platform operating in the UK, Germany, France, and Ireland.

“This acquisition, announced in June 2025, grants Hims & Hers access to over 1.3 million active customers and nearly 2.3 million consultations delivered in 2024 by ZAVA’s in-house medical team,” Zacks noted.

“The integration of ZAVA’s technology with Hims & Hers’ established brand positions it to deliver personalized, seamless digital healthcare across key European markets,” it added.

While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.